BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today 2019;49:894-906. [PMID: 30949842 DOI: 10.1007/s00595-019-01804-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020;4:6-13. [PMID: 32021953 DOI: 10.1002/ags3.12295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
2 Park SJ, Kim JH, Joo I, Han JK. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT. Abdom Radiol (NY) 2021;46:4765-78. [PMID: 34085090 DOI: 10.1007/s00261-021-03127-3] [Reference Citation Analysis]
3 Mita N, Iwashita T, Ichikawa H, Iwasa Y, Uemura S, Murase K, Shimizu M. Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center. J Clin Med 2021;10:2848. [PMID: 34199125 DOI: 10.3390/jcm10132848] [Reference Citation Analysis]
4 Takano N, Yamada S, Sonohara F, Inokawa Y, Takami H, Hayashi M, Koike M, Fujii T, Kodera Y. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. Surg Today 2021;51:1099-107. [PMID: 33483785 DOI: 10.1007/s00595-020-02220-2] [Reference Citation Analysis]
5 Mataki Y, Kurahara H, Idichi T, Tanoue K, Hozaka Y, Kawasaki Y, Iino S, Maemura K, Shinchi H, Ohtsuka T. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. Cancers (Basel) 2021;13:1057. [PMID: 33801465 DOI: 10.3390/cancers13051057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hatsuzawa Y, Yamaguchi K, Takanashi T, Sato I, Tamai K, Mochizuki M, Iwai W, Wakui Y, Abue M, Yamamoto K, Yasuda J, Mizuma M, Unno M, Sugamura K. CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells. Pancreatology 2020;20:493-500. [PMID: 32007357 DOI: 10.1016/j.pan.2020.01.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Attard JA, Farrugia A, Pathanki A, Roberts KJ, Dasari B, Isaac J, Ma YT, Chatzizacharias NA. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review. Pancreas 2020;49:1264-75. [PMID: 33122513 DOI: 10.1097/MPA.0000000000001694] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Nie D, Lai G, An G, Wu Z, Lei S, Li J, Cao J. Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer. Front Oncol 2021;11:719253. [PMID: 34604055 DOI: 10.3389/fonc.2021.719253] [Reference Citation Analysis]
9 Mitachi K, Ariake K, Shima H, Sato S, Miura T, Maeda S, Ishida M, Mizuma M, Ohtsuka H, Kamei T, Igarashi K, Unno M. Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer. Sci Rep 2021;11:6541. [PMID: 33753854 DOI: 10.1038/s41598-021-86099-0] [Reference Citation Analysis]
10 Wei M, Shi S, Hua J, Xu J, Yu X; Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open 2019;9:e033452. [PMID: 31818843 DOI: 10.1136/bmjopen-2019-033452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Tanaka H, Imai H, Higashi T, Murase K, Matsuhashi N, Yoshida K. Splenic artery transposition for hepatic arterial reconstruction in conversion surgery of an initially unresectable, locally advanced pancreatic cancer after gemcitabine/nab-paclitaxel: A case report. Int J Surg Case Rep 2021;78:192-6. [PMID: 33360334 DOI: 10.1016/j.ijscr.2020.12.041] [Reference Citation Analysis]
12 Motoi F, Unno M. Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol? Ann Gastroenterol Surg 2020;4:100-8. [PMID: 32258974 DOI: 10.1002/ags3.12311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]